Business
Psyence BioMed Announces Results of Annual and Special Meeting of Shareholders
NEW YORK, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a biopharmaceutical company advancing nature-derived psilocybin and ibogaine therapies for unmet mental health needs, today announced the voting results from its Annual and Special Meeting of Shareholders (the “Meeting”), held at 9:00 a.m. Eastern Time on February 12, 2026. Shareholders voted in favour of all matters of business presented at the Meeting, including the election o
About this update from Psyence Biomedical Ltd.
[{"type":"image","alt":"Psyence Biomedical Ltd.","displaySize":"","headline":null,"caption":"Psyence Biomedical Ltd.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":76,"url":"https://media.zenfs.com/en/globenewswire.com/67bd17e4cdd6e19b07d34e625f8a453d"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/4XQTy8kOrKa7B9604uln6w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEwNjtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/67bd17e4cdd6e19b07d34e625f8a453d","width":300,"height":76}},"lazy":false},{"type":"text","content":"NEW YORK, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a biopharmaceutical company advancing nature-derived psilocybin and ibogaine therapies for unmet mental health needs, today announced the voting results from its Annual and Special Meeting of Shareholders (the “Meeting”), held at 9:00 a.m. Eastern Time on February 12, 2026. Shareholders voted in favour of all matters of business presented at the Meeting, including the election of directors, the appointment of auditors and the approval of share consolidation authority for the board of directors (the “Board”).","length":632,"tagName":"p"},{"type":"text","content":"All director nominees listed in the Company’s management information circular dated January 2, 2026 were duly elected as directors of the Company to hold office until the next annual meeting of shareholders or until their successors are elected or appointed. Shareholders approved the appointment of MNP LLP as the Company’s auditors for the ensuing year and authorized the Board to fix the auditors’ remuneration. Shareholders further approved a special resolution authorizing the Board, in its sole discretion, to implement one or more consolidations of the Company’s issued and outstanding common shares, at a ratio of up to 250:1, with such consolidation(s) to be implemented, if at all, at a time and ratio to be determined by the Board.","length":742,"tagName":"p"},{"type":"text","content":"The Company will provide additional disclosure if and when the Board determines to implement any share consolidation, including the final consolidation ratio and effective date, subject to applicable regulatory and exchange approvals.","length":234,"tagName":"p"},{"type":"text","content":"Further details regarding the matters voted on at the Meet...